NO20044947L - MUC-1 antigen med redusert antall VNTR gjentagene enheter - Google Patents

MUC-1 antigen med redusert antall VNTR gjentagene enheter

Info

Publication number
NO20044947L
NO20044947L NO20044947A NO20044947A NO20044947L NO 20044947 L NO20044947 L NO 20044947L NO 20044947 A NO20044947 A NO 20044947A NO 20044947 A NO20044947 A NO 20044947A NO 20044947 L NO20044947 L NO 20044947L
Authority
NO
Norway
Prior art keywords
muc
nucleic acid
repeating units
pharmaceutical compositions
vntr
Prior art date
Application number
NO20044947A
Other languages
English (en)
Other versions
NO20044947D0 (no
Inventor
Jonathan Henry Ellis
Neil Burden
Paul A Hamblin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20044947D0 publication Critical patent/NO20044947D0/no
Publication of NO20044947L publication Critical patent/NO20044947L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår nye nukleinsyrekonstruksjoner, nyttige i fremgangsmåter for nukleisyrevaksinering for behandling og profylakse av MUC-1 - uttrykkende tumorer. Spesielt er nukleinsyren DNA og DNA-konstruksjonene omfatter et gen som koder for et MUC-1-derivat som har mindre enn 10 perfekt repeterte enheter. Oppfinnelsen tilveiebringer videre farmasøytiske sammensetninger omfattende nevnte konstruksjoner, spesielt farmasøytiske sammensetninger egnet for partikkelmediert levering, fremgangsmåter for fremstilling av dem, og deres anvendelse i medisin. Nye proteiner som kodes for av nukleinsyren og farmasøytiske sammensetninger som inneholder dem tilveiebringes også.
NO20044947A 2002-05-24 2004-11-12 MUC-1 antigen med redusert antall VNTR gjentagene enheter NO20044947L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines
PCT/EP2003/005594 WO2003100060A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units

Publications (2)

Publication Number Publication Date
NO20044947D0 NO20044947D0 (no) 2004-11-12
NO20044947L true NO20044947L (no) 2005-12-16

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044947A NO20044947L (no) 2002-05-24 2004-11-12 MUC-1 antigen med redusert antall VNTR gjentagene enheter

Country Status (20)

Country Link
US (1) US20060251665A1 (no)
EP (1) EP1527177A2 (no)
JP (1) JP2005526520A (no)
KR (1) KR20050004211A (no)
CN (1) CN100408682C (no)
AR (1) AR039846A1 (no)
AU (1) AU2003240729B2 (no)
BR (1) BR0311211A (no)
CA (1) CA2485816A1 (no)
GB (1) GB0212046D0 (no)
IL (1) IL165156A0 (no)
IS (1) IS7526A (no)
MX (1) MXPA04011527A (no)
NO (1) NO20044947L (no)
NZ (1) NZ536668A (no)
PL (1) PL374569A1 (no)
RU (1) RU2303069C2 (no)
TW (1) TW200407426A (no)
WO (1) WO2003100060A2 (no)
ZA (1) ZA200409445B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
DK1694364T3 (da) * 2003-11-12 2014-07-21 Us Government System til behandling og forebyggelse af brystcancer
WO2005046622A2 (en) * 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2800911A1 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
EP2678005A4 (en) * 2011-02-24 2015-06-10 Oncothyreon Inc GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
MX2018008797A (es) * 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
CN110198733B (zh) * 2016-09-28 2024-04-30 巴法里安诺迪克有限公司 用于增强痘病毒中转基因的稳定性的组合物和方法
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
ES2375992T3 (es) * 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
RU2303069C2 (ru) 2007-07-20
AR039846A1 (es) 2005-03-02
IL165156A0 (en) 2005-12-18
ZA200409445B (en) 2006-02-22
JP2005526520A (ja) 2005-09-08
US20060251665A1 (en) 2006-11-09
NO20044947D0 (no) 2004-11-12
CN100408682C (zh) 2008-08-06
AU2003240729B2 (en) 2007-12-20
PL374569A1 (en) 2005-10-31
CN1668746A (zh) 2005-09-14
CA2485816A1 (en) 2003-12-04
BR0311211A (pt) 2005-03-01
GB0212046D0 (en) 2002-07-03
RU2004134331A (ru) 2005-08-27
IS7526A (is) 2004-11-11
NZ536668A (en) 2007-01-26
AU2003240729A1 (en) 2003-12-12
WO2003100060A2 (en) 2003-12-04
WO2003100060A3 (en) 2004-02-19
KR20050004211A (ko) 2005-01-12
EP1527177A2 (en) 2005-05-04
TW200407426A (en) 2004-05-16
MXPA04011527A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
Ebensen et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
NO20044947L (no) MUC-1 antigen med redusert antall VNTR gjentagene enheter
RU2583295C2 (ru) Нуклеиновая кислота, содержащая или кодирующая гистоновую структуру типа "стебель-петля" и поли(а)-последовательность или сигнал полиаденилирования, для повышения экспрессии кодируемого белка
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
WO2002062378A3 (en) Hyperblebbing bacterial strains and use thereof for production of vaccines
EP2773760B1 (en) Double-stranded rna for immunostimulation
US6090791A (en) Method for inducing mucosal immunity
AU2003263552A1 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
FI902569A0 (fi) Producering av till gonorre anslutande pi-proteiner och vaccin.
ATE332379T1 (de) Menschliche dnase resistent gegen actininhibitoren
ATE296354T1 (de) Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen
ES2264700T3 (es) Preparacion de una proteina recombinante en una celula huesped procariotica mediante el uso de un codon mejorado.
CN103012577B (zh) 一种重组猪白细胞介素4及其编码基因和表达方法
WO2002098455A3 (en) Production of recombinant human arylsulfatase a
NO20081541L (no) Ny sjo-lus vaksine
Wang et al. Role of PG0192 and PG0193 in the modulation of pro‐inflammatory cytokines in macrophages in response to Porphyromonas gingivalis
Madison et al. Partial digestion of a yeast lysine transfer ribonucleic acid and reconstruction of the nucleotide sequence
Yen et al. Biological activity of ovine IL-23 expressed using a foot-and-mouth disease virus 2A self-cleaving peptide
CN112725378B (zh) 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
EP4121531A1 (en) Compositions and methods comprising improved guide rnas
CN105713916A (zh) 一种铜绿假单胞菌基因及其dna疫苗
CN118812671B (zh) 一种蛋白质、自复制mRNA分子及一种狂犬病毒saRNA疫苗
RU2006125511A (ru) Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых
TW202523844A (zh) 用於表現ｅｇｆｒ的組合物和方法
WO2026062371A2 (en) Optimised rnas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application